Sadik H. Kassim

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2018 · 1.8K citations · Full text

Life Sciences, Immunology, Oncology +16

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran et al. · Clinical Cancer Research · 2014 · 801 citations · Full text

Medicine, Immunology, Oncology +17

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter et al. · Blood · 2013 · 590 citations · Full text

Medicine, Hematology, Immunology +13

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

Ling Zhang, Richard A. Morgan, Joal D. Beane et al. · Clinical Cancer Research · 2015 · 452 citations · Full text

Medicine, Immunology, Oncology +17